MINERALYS THERAPEUTICS INC (MLYS)

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

Company Info

MINERALYS THERAPEUTICS INC

150 N. Radnor Chester Road, Suite F200

Radnor PENNSYLVANIA

P: 18883786240

Employees: 28

Website: https://mineralystx.com/